Could a cold virus drug prevent COPD Flare-Ups?

NCT ID NCT06149494

Completed Disease control Sponsor: Altesa Biosciences, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether the drug vapendavir can reduce breathing problems in people with COPD who catch a rhinovirus (common cold). Fifty-two adults with COPD were given either vapendavir or a placebo after being exposed to the virus. The main goal was to see if vapendavir lowered the severity of symptoms like cough, wheeze, and shortness of breath over six weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Vapendavir

What this could lead to

If it works, this could point toward a treatment to prevent severe COPD flare-ups caused by the common cold.

What could go wrong

This is a small, early-phase trial (52 people) testing a drug not yet approved. Results may not confirm benefit, and safety is still being evaluated.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INFECTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease common cold COPD, severe early onset enterovirus infectious disease Infections infectious disease lower respiratory tract disorder lung disorder obstructive lung disease pulmonary emphysema Respiration Disorders respiratory system disorder respiratory tract infectious disorder RNA Virus Infections upper respiratory tract disorder viral infectious disease viral respiratory tract infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC LOWER RESPIRATORY DISEASES CHRONIC RESPIRATORY DISEASE COPD COPD EXACERBATION ACUTE COPD WITH ACUTE LOWER RESPIRATORY INFECTION EMPHYSEMA OR COPD ENTEROVIRUS ENTEROVIRUS INFECTIONS INFECTION VIRAL INFECTIONS INFECTIONS, RESPIRATORY LOWER RESPIRATORY DISEASE LOWER RESPIRATORY DISORDER LOWER RESPIRATORY TRACT AND LUNG INFECTIONS LUNG DISEASE CHRONIC LUNG DISEASES OBSTRUCTIVE PULMONARY DISEASE PULMONARY DISEASE PULMONARY DISEASE, CHRONIC OBSTRUCTIVE RESPIRATORY COMPLICATION RESPIRATORY DISEASE RESPIRATORY DISEASE CHRONIC RESPIRATORY TRACT DISEASES RESPIRATORY TRACT INFECTIONS RESPIRATORY VIRAL INFECTION RHINOVIRUS RHINOVIRUS INFECTION UPPER RESP TRACT INFECTION UPPER RESPIRATORY DISEASE UPPER RESPIRATORY DISEASE, ACUTE UPPER RESPIRATORY DISORDER UPPER RESPIRATORY INFECTION VIRAL UPPER RESPIRATORY TRACT INFECTIONS VIRAL INFECTION VIRUS DISEASES VIRUS INFECTION, RNA

Contacts and locations

Show contact details

Locations

St. Mary's Hospital - Imperial College Respiratory Research Unit (ICRRU)

London, W2 1NY, United Kingdom